A phase 1 clinical trial of SC 0062
Latest Information Update: 25 Jan 2023
At a glance
- Drugs SC-0062 (Primary)
- Indications Diabetic nephropathies; IgA nephropathy
- Focus Adverse reactions; First in man
Most Recent Events
- 25 Jan 2023 New trial record
- 19 Dec 2022 Results presented in a WuXi Biologics Media Release.